Adaptive Biotechnologies
Adaptive Biotechnologies Revenues Rise 22 Percent in Q3
The firm's MRD revenue rose 52 percent year over year, while immune medicine revenue declined 32 percent.
Adaptive Biotechnologies Test Receives Expanded Medicare Coverage for Mantle Cell Lymphoma
The firm's blood-based ClonoSeq test can be used to assess response to treatment, understand prognosis, and monitor patients to detect molecular recurrence.
360Dx Top 30 Inches up 1 Percent in September
Of the 30 companies in the index, 13 saw their stock prices increase, 15 saw their share prices decline, and two firms' stock prices remained essentially flat.
Adaptive Biotechnologies Gets IVDR Class C Certification for ClonoSeq Assay
The certification makes the ClonoSeq assay available to EU patients and enables Adaptive to process EU clinical trial samples in its US laboratory.
Adaptive Biotechnologies Q2 Revenues Drop 12 Percent as MRD Revenues Soar
The Seattle-based company saw 36 percent growth in its minimal residual disease business while making significant progress in curbing operating expenses.
Jun 4, 2024
360Dx Top 30 Rises 3 Percent in May
May 1, 2024
360Dx Top 30 Falls 6 Percent in April
Apr 1, 2024
360Dx Top 30 Rises 3 Percent in March
May 1, 2023